Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on June 4.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Risinger has given his Buy rating due to a combination of factors related to Centessa Pharmaceuticals’ ongoing developments and potential. The company’s orexin agonist program, particularly the ORX750, is expected to show a superior benefit-risk profile when Phase 2 results are released. Despite concerns about adverse events associated with orexin agonists, management has clarified that these comments were about competitors’ data, not Centessa’s ongoing trials.
The innovative design of the ORX750 Phase 2a trial, which involves unblinding after each dose level, sets it apart from competitor studies that focus on specific doses. This approach may provide more comprehensive insights into the drug’s efficacy and safety over time. Additionally, the anticipation of data disclosure across multiple indications by 2025 adds to the stock’s appeal, suggesting that the current market valuation may not fully reflect the company’s potential.
CNTA’s price has also changed moderately for the past six months – from $17.490 to $11.860, which is a -32.19% drop .